Atea’s woes grow while other Covid readouts approach
Big upcoming events include data from a trial of Pfizer’s oral antiviral Paxlovid in patients at risk of severe illness.
Esmo IO 2021 – Propel fails to propel Nektar
The focus now falls on first-line melanoma data with bempegaldesleukin plus Opdivo, due in early 2022.
Idorsia sets itself up for failure
Cenerimod flunks a mid-stage lupus study, so Idorsia moves to go straight into phase 3. What can possibly go wrong?
